centerforbiosimilars1h
The Top 5 Biosimilar Articles for the Week of January 27
Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...
centerforbiosimilars21h
Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in Psoriasis
SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.
centerforbiosimilars1d
FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara Biosimilar
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
centerforbiosimilars1d
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
centerforbiosimilars3d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
centerforbiosimilars4d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars5d
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...